Momenta Pharmaceuticals (MNTA -1.8%) lands on the radar of analysts due to a lush collaboration...


Momenta Pharmaceuticals (MNTA -1.8%) lands on the radar of analysts due to a lush collaboration deal it scored with Baxter and its strategic position in the growing "biosimilars" field. One estimate has the market for biotech generics running as high as $5B over the next few years, with drug offerings from firms such as MNTA and BIIB looking as a cheaper alternatives for strapped health care programs.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs